FORM PTO-1449 US Dept. of Commerce				ATTORNEY DOCKET NO. SERIAL NO.					
Patent and Trademark Office				4121-135	10/049,404				
				APPLICANT					
INFORMATION DISCLOSURE TATEMENT O									
(use several sheets if necessary)				Michaela Arndt FILING DATE GROUP					
(use several sheets in heressary)				TIEMO DATE		1644 T			
				February 5, 2002 Not ye			assigned.		
EXAMINER PATENT DOCUMENTS FILING DATE									
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	IF APPRO		
C.C.	AA-	5,643,759	7/1/97	Pfreundschuh	atu	consi	donad	$oldsymbol{ol}}}}}}}}}}}}}}}}}$	
C-C.	AB	6,294,167	9/25/01	Lindhofer et al.					
FOREIGN PATENT DOCUMENTS									
	DOCUMENT PUBLICATION			TRANSLATION					
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
C-C.	AC	DE 43 37 197	10/30/93	Germany	9			_	
C.C.	AD	DE 195 31 346	8/25/95	Germany					
C. (.	AE	DE 198 38 967	2/6/98	Germany					
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)									
~	AF	XP-002115487. "Bispecific CD3 X CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B							
C.C.	<u> </u>	Cells." Kipriyanov et al. Int. J. Cancer: 77, 763-771 (1998).							
	AG	"Anti-CD16/CD39 hispecific antibodies as possible treatment for refractory Hodgkin's Disease." Hartmann et al., Leuk & Lyph., 1998. Vol.31. patent. 385-392.							
C.C.	AH	XP 000653169. 609. Klimka et al.							
	ΑI	XP-002153101. "A bispecific diabody that mediates natural killer cell cytotoxicity against							
		exmotransplantated human Hodgkin's tumors." Arndt et al. Blood, Vol. 94, No. 8 (October 15), 1999: patent 2562-2568.							
		Already considered (Duplicative)							
									
		•							
·									
							 -		
									
 	L	<u> </u>							
EXAMINER						ONSIDERED			
en eg						8/11/0	6		